Overall, our study shows that pembrolizumab treatment resulted in a successful remission of metastatic melanoma in a HIV-1-infected individual, and concomitantly enhanced the HIV-1 specific-CD8+ T-cell response in terms of activation and function. This evidence concerns the gene CD8A and metastatic melanoma.